Portfolio Lab

Puma Biotechnology, Inc.

  • Stock
  • Ticker PBYI
  • Nasdaq

Health care · Pharmaceuticals · USA

$7.05 −0.98%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Puma Biotechnology, Inc. since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

PBYIGlobal equities (VT)

$10,000 grew to $1,610. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −98.8% in 05/2022, measured from the peak in 11/2017. The old peak has not been reached again yet.

1-year return
+45.7%
5-year return p.a.
+15.6%
10-year return p.a.
−16.7%
Volatility p.a.
80.5%
Largest decline
−98.8%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue5946525475455755
Gross profit4535404252344440
Operating income134.06.69.617-3.87.65.3
EBITDA166.86.79.720-1.2107.7
Net income193.05.98.813-3.88.26.0
Earnings per share0.400.060.120.170.26-0.070.160.11
Balance sheet
Total assets213196195203216193193203
Liabilities12199908886645456
Equity9297105115130128139147
Cash6963555430363742
Long-term debt2211110.00.00.00.0–
Cash flow
Operating cash flow163.6149.714151.615
Capital expenditure0.0-0.10.00.00.00.00.00.0
Free cash flow163.6149.714151.615

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2017 at +222.0%, weakest 2018 at −79.4%. 5 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
9 Nov 2026$0.11
6 Aug 2026$0.16
7 May 2026−$0.07
26 Feb 2026$0.26
6 Nov 2025$0.17
7 Aug 2025$0.12
8 May 2025$0.06
27 Feb 2025$0.40
7 Nov 2024$0.41
1 Aug 2024−$0.09
2 May 2024−$0.10
29 Feb 2024$0.25

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€330m
Market cap in trading currency
$364m
Enterprise value
$256m
P/E
15.3
P/S
1.57
P/B
2.49
EV/Sales
1.10
EV/EBITDA
7.0
Earnings yield
6.5%
FCF yield
12.6%

Results (last four quarters)

Revenue
$232m
Gross profit
$171m
EBITDA
$36.3m
Net income
$23.8m
Earnings per share
$0.46
Revenue per share
$4.48
Revenue growth
+1.1%
Earnings growth
−32.7%

Profitability

Gross margin
73.6%
Operating margin
11.3%
Net margin
10.3%
Return on equity
18.2%
Return on assets
11.8%

Balance sheet and cash flow

Cash
$109m
Cash per share
$2.10
Financial debt
$0
Debt/equity %
0
Current ratio
3.03
Book value per share
$2.84
Operating cash flow
$46.0m
Free cash flow
$46.1m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
51.7m
Volume
861,208
Avg. volume 3 months
366,692
Relative volume
2.3

Price and technicals

Price
$7.05
1 day
−1.0%
52-week high
$11.26
52-week low
$4.84
Distance to 52-week high
−37.4%
Distance to 52-week low
+45.7%
Distance to 50-day line
−26.1%
Distance to 200-day line
−12.3%
RSI (14)
24
Volatility 1M
69.1%

Performance

1 week
−9.3%
1 month
−37.4%
3 months
−22.7%
6 months
−0.4%
YTD
+18.5%
1 year
+44.3%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has PBYI performed since 11/2016?

$10,000 grew to $1,610 by 20 Nov 2026, which is −16.7% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is PBYI?

Volatility was 80.5% per year, measured on monthly returns. The largest decline from a peak was −98.8%, with the low in 05/2022.

How does PBYI compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, PBYI returned −16.7% at 80.5%. The correlation of monthly returns was 0.29; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.